Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
•
Hospital Medicine
Do you prefer using unfractionated heparin or low molecular weight heparin in stable patients presenting with NSTE ACS awaiting primary PCI (assuming normal renal function)?
Related Questions
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
In light of recent trials evaluating NPO before cath (CHOW NOW, SCOFF, etc.) are centers still restricting oral intake pre-procedure?
What has been your approach to percutaneous intervention for calcified nodules and threshold for intervention?
What are the best techniques to reduce POCUS artifact and increase the diagnostic accuracy of lung ultrasound?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
When differentiating and treating patients with shock (distributive/cardiogenic), how reliable would you consider the noninvasive clinical platform (EV1000) when derived from peripheral arterial lines?
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
